Published: Sat, October 07, 2017
Medicine | By Earnest Bishop

CytomX Therapeutics, Inc. (CTMX) Reached a 52-Week High

CytomX Therapeutics, Inc. (CTMX) Reached a 52-Week High

Bank of America Corporation's price target points to a potential upside of 54.13% from the company's current price.

Several other equities research analysts have also recently weighed in on CTMX.

Investors may be interested in viewing the Gross Margin score on shares of CytomX Therapeutics, Inc. Cann reiterated a "hold" rating on shares of CytomX Therapeutics in a research report on Tuesday, August 8th. At present, 0 analysts call it Sell, while 1 think it is Hold. Cowen and Company reiterated an "outperform" rating on shares of CytomX Therapeutics in a report on Thursday. (NASDAQ:CTMX) in a research report released on Thursday.

On September 8 analysts at Wedbush started coverage with a rating of "Outperform". CytomX Therapeutics has a consensus rating of Hold and a consensus price target of $32.67.

CytomX Therapeutics (NASDAQ:CTMX) last announced its quarterly earnings results on Monday, August 7th. About 444,671 shares traded or 4.27% up from the average. The stock's market cap is $792.64 million. Amgen and CytomX Therapeutics plan to jointly develop a CytomX Probody T-cell engaging bispecific antibody against EGFR (Epidermal Growth Factor Receptor). The 50 day moving average was up $5.14 or +30.37% and the 200 day average went up by +41.19%. Also, CFO Debanjan Ray sold 2,500 shares of CytomX Therapeutics stock in a transaction that occurred on Wednesday, August 9th.

As of the last earnings report the EPS was $-1.70 and is projected to be $-1.49 for the current year with 36,867,000 shares now outstanding. The company had revenue of $8.75 million during the quarter, compared to the consensus estimate of $4.95 million. Amgen will lead global commercial activities with CytomX able to opt into a profit share in the US and receive tiered, double-digit royalties on net product sales outside of the U.S. Next quarter's EPS is estimated at $-0.41 with next year's EPS anticipated to be $-1.38. If you are viewing this piece on another domain, it was stolen and reposted in violation of United States & worldwide copyright and trademark legislation. If you are viewing this news story on another publication, it was illegally stolen and republished in violation of US & global copyright law. Below is a list of CytomX Therapeutics Inc (NASDAQ:CTMX) latest ratings and price target changes. William Michael Kavanaugh sold 48,368 shares at an average price of $24.34 on October 4th. The shares were purchased at an average price of $18.57. Gluck now owns $7,563,576 of the stock according to the SEC filing.

Currently, the 14-day Relative Strength Index (RSI) reading is at 83.09. They now have a Dollars 30 price target on the stock. The disclosure for this sale can be found here.

Sonny Melton's father reacts to son being a victim in Vegas massacre
A woman who on Twitter has described herself as a close friend told Heavy .com that Gomez had been in training to become a nurse. Bruce Ure, deputy police chief of the small Texas city of Seguin, was in the concert's VIP section when the gunfire broke out.

Traders are feeling more bearish on shares of the company of late if you evaluate the motion in short interest. The Logan Capital Management Inc holds 155,266 shares with $11.26M value, down from 162,261 last quarter.

Sean A. Mccarthy, President and CEO let go of $177,566 worth of shares at an average price of $18.57 on Monday the 2nd.

Let's take an assessment at how CytomX Therapeutics, Inc. Dev. now owns $338,740 of the stock per an SEC filing yesterday. Cubist Systematic Strategies LLC bought a new stake in CytomX Therapeutics in the second quarter valued at $174,000. Legal & General Group Plc now owns 6,448 shares of the biotechnology company's stock worth $101,000 after buying an additional 1,434 shares during the last quarter.

The share price of the company (NASDAQ:CTMX) was down -4.46%, with a high of 23.17 during the day and the volume of CytomX Therapeutics, Inc. shares traded was 650923.

CytomX Therapeutics, Inc., launched on September 16, 2010, is a clinical-stage, oncology-focused biopharmaceutical company.

"Probody-based T-cell-engaging bispecific antibodies offer significant potential in treating cancers by employing localized therapeutic activity within tumor tissue", added CytomX president and CEO Sean McCarthy, D.Phil. "Development of Probody-based T-cell-engaging bispecifics further validates the broad applicability of the Probody platform in addressing unmet needs in oncology". The Company's pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.

Like this: